DISHMAN PHARMA | NEULAND LABS | DISHMAN PHARMA/ NEULAND LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | 71.5 | 35.1% | View Chart |
P/BV | x | 3.3 | 2.5 | 131.3% | View Chart |
Dividend Yield | % | 0.7 | 0.1 | 468.7% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
NEULAND LABS Mar-20 |
DISHMAN PHARMA/ NEULAND LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 754 | 49.7% | |
Low | Rs | 129 | 247 | 52.1% | |
Sales per share (Unadj.) | Rs | 197.8 | 594.5 | 33.3% | |
Earnings per share (Unadj.) | Rs | 21.2 | 12.6 | 167.9% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 37.0 | 93.8% | |
Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 100.0% | |
Dividend yield (eoy) | % | 0.8 | 0.4 | 198.9% | |
Book value per share (Unadj.) | Rs | 179.9 | 553.4 | 32.5% | |
Shares outstanding (eoy) | m | 80.69 | 12.83 | 628.9% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 0.8 | 151.1% | |
Avg P/E ratio | x | 11.9 | 39.6 | 30.0% | |
P/CF ratio (eoy) | x | 7.2 | 13.5 | 53.6% | |
Price / Book Value ratio | x | 1.4 | 0.9 | 154.7% | |
Dividend payout | % | 9.4 | 15.8 | 59.6% | |
Avg Mkt Cap | Rs m | 20,306 | 6,421 | 316.2% | |
No. of employees | `000 | 0.8 | 1.3 | 64.7% | |
Total wages/salary | Rs m | 5,355 | 1,236 | 433.4% | |
Avg. sales/employee | Rs Th | 19,252.7 | 5,949.4 | 323.6% | |
Avg. wages/employee | Rs Th | 6,459.5 | 963.8 | 670.2% | |
Avg. net profit/employee | Rs Th | 2,064.1 | 126.4 | 1,632.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 7,627 | 209.3% | |
Other income | Rs m | 265 | 39 | 683.1% | |
Total revenues | Rs m | 16,226 | 7,666 | 211.7% | |
Gross profit | Rs m | 4,103 | 1,019 | 402.7% | |
Depreciation | Rs m | 1,091 | 313 | 348.7% | |
Interest | Rs m | 944 | 216 | 437.8% | |
Profit before tax | Rs m | 2,334 | 529 | 441.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | 367 | 169.9% | |
Profit after tax | Rs m | 1,711 | 162 | 1,055.7% | |
Gross profit margin | % | 25.7 | 13.4 | 192.4% | |
Effective tax rate | % | 26.7 | 69.4 | 38.5% | |
Net profit margin | % | 10.7 | 2.1 | 504.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 5,152 | 213.9% | |
Current liabilities | Rs m | 9,517 | 3,576 | 266.1% | |
Net working cap to sales | % | 9.4 | 20.7 | 45.5% | |
Current ratio | x | 1.2 | 1.4 | 80.4% | |
Inventory Days | Days | 110 | 105 | 105.2% | |
Debtors Days | Days | 35 | 91 | 38.3% | |
Net fixed assets | Rs m | 16,304 | 3,969 | 410.8% | |
Share capital | Rs m | 161 | 129 | 125.1% | |
"Free" reserves | Rs m | 12,907 | 6,971 | 185.2% | |
Net worth | Rs m | 14,516 | 7,100 | 204.5% | |
Long term debt | Rs m | 4,189 | 774 | 541.5% | |
Total assets | Rs m | 29,805 | 12,310 | 242.1% | |
Interest coverage | x | 3.5 | 3.5 | 100.5% | |
Debt to equity ratio | x | 0.3 | 0.1 | 264.8% | |
Sales to assets ratio | x | 0.5 | 0.6 | 86.4% | |
Return on assets | % | 8.9 | 3.1 | 290.3% | |
Return on equity | % | 11.8 | 2.3 | 516.4% | |
Return on capital | % | 17.5 | 9.5 | 185.3% | |
Exports to sales | % | 24.8 | 0 | - | |
Imports to sales | % | 3.7 | 0 | - | |
Exports (fob) | Rs m | 3,956 | NA | - | |
Imports (cif) | Rs m | 596 | NA | - | |
Fx inflow | Rs m | 4,952 | 5,187 | 95.5% | |
Fx outflow | Rs m | 697 | 1,593 | 43.7% | |
Net fx | Rs m | 4,255 | 3,594 | 118.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 573 | 485.9% | |
From Investments | Rs m | -1,529 | -487 | 314.1% | |
From Financial Activity | Rs m | -941 | -55 | 1,717.3% | |
Net Cashflow | Rs m | 316 | 33 | 970.6% |
Indian Promoters | % | 61.4 | 36.3 | 169.3% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 3.7 | 63.7 | 5.8% | |
FIIs | % | 12.7 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 63.7 | 34.7% | |
Shareholders | 46,261 | 12,705 | 364.1% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: FRESENIUS KABI ONCO. AJANTA PHARMA ALEMBIC ALKEM LABORATORIES CADILA HEALTHCARE
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets ended at record-high levels yesterday with Nifty ending above 14,600-mark.
Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More